CD Access is a nonprofit that provides patients access to drugs and therapies that are currently unavailable through clinical trial or prescription. CD Access’ first program allows Duchenne muscular dystrophy patients in Canada that previously participated in a clinical trial for drisapersen to begin redosing through a Health Canada Special Access Programme.
BioMarin transferred their supply of exon 51 skipping drug, drisapersen, to CD Access for distribution to boys who were participants in previous clinical trials in Canada. Former trial participants in Canada will need to contact their physician to confirm eligibility. The drug will be administered at Children’s Hospital of Western Ontario, Children’s Hospital of Eastern Ontario, Children’s & Women’s Health Centre of BC and potentially one additional site in Canada.